Skip to main content
Michael Eisenstein on Muck Rack

Michael Eisenstein

Verified
As seen in: British Journal of Cancer, Nature, Weird Fiction Review Edu, Scientific American, American Chemical Society, Chemical & Engineering News (C&EN), The Hub (Johns Hopkins University), Science Magazine, Medical Xpress, BioRxiv and
Covers:  Biology, Medicine, Genomics, Biotechnology, Drug Development, Research Policy, Bioethics, Regenerative Medicine, Oncology, Synthetic Biology, Immunotherapy
Science writer and editor. Done with this place. Find me on BlueSky, same name.

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Michael Eisenstein’s Journalist Portfolio

See all →
Single-cell RNA-seq analysis software providers scramble to offer solutions

Single-cell RNA-seq analysis software providers scramble to offer solutions

A raft of tools have sprung up to help biologists work through the single-cell transcriptomic bottleneck, but…

View article →
Rewriting the regenerative rulebook

Rewriting the regenerative rulebook

Adult stem cells have become a regulatory battleground as clinicians, scientists and ethicists debate whether…

View article →
Pursuing the simple life

Pursuing the simple life

Efforts to pare away cellular genomes are yielding streamlined biosynthetic factories and deeper insights int…

View article →
Organoids: the body builders

Organoids: the body builders

Stem-cell-derived organoids offer increasingly sophisticated models for studying human development and diseas…

View article →
How social scientists can help to shape climate policy

How social scientists can help to shape climate policy

Developing strategies to ensure that the ‘needs of the few’ do not outweigh those of the rest.

View article →
An ace in the hole for DNA sequencing

An ace in the hole for DNA sequencing

Offering long reads and rapidly improving accuracy, nanopore sequencing has the potential to upend the DNA se…

View article →

Articles

Editor’s pick: Trogenix - Nature Biotechnology

|
By Michael Eisenstein Verified
| Nature Verified
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Trogenix has developed a platform for generating ‘synthetic super-enhancers’ that could drive highly cell-specific gene therapy-based treatment of solid tumors such as glioblastoma. Enjoying our latest content?
Open in Who Shared View Duplicates (2) Issue with article?

An innovative technology boosts image quality for protein structures

|
By Michael Eisenstein Verified
| Nature Verified
An engineer at Biohub in Redwood City, California, makes adjustments to the laser phase plate cavity inside a cryo-electron microscope.Credit: Biohub For 15 years, structural biologists have debated the feasibility of a technology that could improve the resolution of protein structures produced by cryo-electron microscopy (cryo-EM).
Open in Who Shared Issue with article?

‘Virtual cells’ aim to turn raw data into predictive models of biology

|
By Michael Eisenstein Verified
| Nature Verified
As every gamer knows, computers can plausibly simulate just about anything from the routine concerns of a household to the crises confronting a multiplanetary civilization. Simulating the fundamental unit of life — the cell — should be a walk in the park. But it’s not. Each cell is a complex ecosystem of biomolecules that interact with one another and react to external cues in ways that remain poorly understood. And what’s true of one cell type isn’t necessarily true of another.
Open in Who Shared Issue with article?
See all 317 licensed articles (318 Total)